Despite a 48 percent increase in third quarter global sales of Eylea (aflibercept) compared to the same period a year earlier, to $722 million, including 23 percent growth in U.S. sales, shares of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)dipped 5.8 percent Tuesday as investors fretted over more conservative estimates for full-year sales.